Local Recurrence Significantly Increases the Risk of Metastatic Uveal Melanoma

Size: px
Start display at page:

Download "Local Recurrence Significantly Increases the Risk of Metastatic Uveal Melanoma"

Transcription

1 Local Recurrence Significantly Increases the Risk of Metastatic Uveal Melanoma The Ophthalmic Oncology Task Force Purpose: To assess of the effect of local recurrence of uveal melanoma on metastasis using a multicenter international tumor registry. Design: Retrospective study using an online tumor registry. Participants: Patients with uveal melanoma diagnosed between 2001 and Methods: A committee was formed to create uveal melanoma patient-specific data fields. Ten subspecialty ophthalmic oncology centers from 4 continents shared data. Patient selection criteria included diagnosis of uveal melanoma and adequate records to allow tumor staging by American Joint Committee on Cancer (AJCC) criteria and follow-up for metastatic melanoma. Main Outcome Measures: Local tumor recurrence and metastatic uveal melanoma. Results: Of 3809 total entries, 3217 patients with ciliary body and choroidal (CBC) melanoma and 160 with iris melanoma were evaluated. There was a median follow-up of 3.7 years (95% confidence interval [CI], 3.5e3.8). One hundred fifty-two patients (4.7%) with CBC melanoma experienced local recurrence, with a cumulative incidence of 11%. Kaplan-Meier point estimates for remaining free of local recurrence were 99% (95% CI, 99e99) at 1 year, 93% (95% CI, 92e94) at 5 years, and 89% (95% CI, 86e91) at 10 years. Five- and 10-year metastasisfree Kaplan-Meier estimates for the recurrence-free group were 87% (95% CI, 86e89) and 82% (95% CI, 79e84), and those for the local recurrence group were 71% (95% CI, 62e78) and 62% (95% CI, 49e72). The difference between these 2 groups was statistically significant (P < 0.001). Furthermore, local tumor recurrence increased the risk of metastasis by a hazard ratio (HR) of 6.28 (95% CI, 4.4e8.9; P < 0.001). Local recurrence was detected up to 9.8 years after treatment. Extrascleral extension also was associated with local recurrence (HR, 3.2; 95% CI, 1.5e6.7; P ¼ 0.003), but higher AJCC T-size category was not (P ¼ 0.63). Five patients (n ¼ 5/161 [3.1%]) with iris melanoma demonstrated local recurrence and 1 metastasized. Conclusions: International multicenter data sharing was used to evaluate the effect of local tumor recurrence on metastatic rate. In that local tumor recurrence was associated with a significantly higher risk of systemic metastasis, effective initial treatment and long-term surveillance of treated uveal melanoma patients is necessary. Ophthalmology 2016;123:86-91 ª 2016 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license ( Supplemental material is available at Local tumor control is a primary goal in the treatment of cancer. 1 In 2002, the Collaborative Ocular Melanoma Study reported that local treatment failure occurred in 10.3% of Collaborative Ocular Melanoma Study patients who underwent iodine 125 plaque brachytherapy. 2 More recent studies, including a literature review of 49 articles, revealed local recurrence rates ranging from 0% to 55.6%. 3 Local orbital recurrence rates after enucleation are poorly documented, but are believed to be less than 1%. 4 These data are important, in that local tumor recurrence is a complication thought to be associated with an increased risk of uveal metastasis and thus decreased survival. 5e8 However, this current assumption that recurrence equals increased risk is supported by a relatively few, small singlecenter studies and 1 multicenter study; all are limited to 70 or fewer patients with local recurrence. 6e8 The Ophthalmic Oncology Task Force comprises members of the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control and includes eye cancer specialists from around the world. 9 For this study, 10 centers pooled their uveal melanoma patient data in an effort to study this disease. 10 We first used this database successfully to test the seventh edition AJCC uveal melanoma staging system. 11 In this study, we analyzed the data to define the relationships among local recurrence, extrascleral extension (EXE), and AJCC tumor size (T size). However, our primary goal was to investigate the largest collection of uveal melanomas with local recurrence and the impact of local recurrence on metastasis-free survival. Methods The Ophthalmic Oncology Task Force collaborated to develop an Internet-based retrospective registry to evaluate uveal melanoma outcomes. The methods of data collection and security have been 86 Ó 2016 by the American Academy of Ophthalmology This is an open access article under the CC BY-NC-ND license ( Published by Elsevier Inc. ISSN /15

2 The Ophthalmic Oncology Task Force Uveal Melanoma Recurrence and Metastasis described previously. 11 Each participating center obtained local ethics and institutional review board approval for participation and entry of patient data into the online database. This study conforms to the Declaration of Helsinki and the Health Insurance Portability and Accountability Act of Patient Eligibility Patient eligibility criteria included patients with primary melanoma of the iris, ciliary body, and choroid consecutively diagnosed and treated in a 10-year span from April 1, 2001 through April 30, Primary tumor treatment methods varied by center, with each type chosen at the discretion of the eye cancer specialists at each center. These were reported to include, but were not limited to, brachytherapy, enucleation or local resection (endoresection and lamellar eye wall resection), transpupillary thermotherapy with and without adjuvant radiation therapy, and stereotactic radiotherapy. However, no numerical treatment-related data were required for this database. Detection of local tumor recurrence was determined by ultrasonography, comparative fundus photography, or inspection and palpation of the anophthalmic orbit (after enucleation). Local recurrence was determined by clinical and imaging studies used at each individual center. There were no exclusions to type of recurrence. Therefore, this study represents site-determined global clinical practice at 10 centers during this decade. Patients were excluded from analysis if they had metastasis (stage 4 disease) at initial staging. Recorded outcome measures included local recurrence and metastasis. There were no limitations on the methods of screening for metastasis. However, these included abdominal ultrasound imaging, computed tomography, magnetic resonance imaging, or combined whole body positron emission tomography and computed tomography, as was the custom and practice at each center. Based on the current assumption that there is no current curative treatment for almost all patients with metastatic uveal melanoma and the recognized difficulties confirming the actual cause of death, this study defined metastasis to be synonymous with metastatic death. Statistical Analysis Categorical variables were described using frequencies and proportions. Time to local recurrence was measured from the date of initial staging. Patients who were alive and free of local recurrence at last follow-up were censored. One hundred thirty patients (4%) died without local recurrence. Because the number of competing risk events (death without local recurrence) was small relative to the size of the data set, these patients were censored at their date of death. Standard methods were used for analysis, rather than implementing competing risks methodology. Kaplan-Meier plots, a standard Cox proportional hazards model, and the log-rank test for trend were implemented to test for a trend relationship between time to local recurrence and T size (based on the AJCC 7th edition criteria). 12 The standard log-rank test was implemented to test for a relationship between time to local recurrence and EXE. Time to metastasis was measured from the date of staging until the date of metastasis; patients who were alive and free of metastasis at last follow-up were censored. Twenty-five patients died without metastasis. Because the number of patients in this latter category was small relative to the size of the data set, these patients were censored at their date of death rather than treating their death as a competing risk event. A Kaplan-Meier plot and the log-rank test were implemented to test for a relationship between time to metastasis and local recurrence at last follow-up. The effect of a local recurrence on the risk of metastasis after staging also was investigated using Cox models, with local recurrence treated as a time-varying covariate. In the univariate model, other factors were not taken into account. An unadjusted (univariate) model and a model adjusted for stage, T-size category, and ciliary body involvement or EXE grouping were implemented. Kaplan-Meier plots, a standard Cox proportional hazards model, and the log-rank test were implemented to test for a relationship between time to local recurrence and EXE. In the analysis of time to metastasis after a local recurrence, only patients who experienced a local recurrence were included. Patients who experienced metastasis before a local recurrence or on the same date as local recurrence were included with their time to metastasis set to years. Those who had no metastasis and no follow-up after their local recurrence were excluded. The related estimates are generalizable to all patients who had a local recurrence. The Kaplan-Meier curves estimate the probability of being free of metastasis after a local recurrence. The 95% confidence limits for this sub-analysis were calculated using the method of Greenwood 13 and the complementary log-log transformation. The survival package in R software (R Core Team, Vienna, Austria) version was used to generate Kaplan-Meier plots; SAS TS level 1M1 version 9.3 software (SAS Inc, Cary, NC) was used to perform all other statistical analyses. Statistical significance was set to Table 1. Summary of Studies Focused on Local Treatment Failure Rates of Choroidal Melanoma and Effect on Metastasis or Death Treatment Authors Method Jampol et al Iodine 125 (COMS) 2 plaque Vrabec et al 8 Cobalt 60 plaque Single or Multicenter Median Follow-up (Range), Years Cajoulle et al 6 Proton beam Single No LR: 3.93 (0e17.84) LR: 5.11 (0.22e17.86) No. of Patients No. of Patients with Local Recurrence Local Failure Incidence (%) Risk of Metastasis or Death Multicenter 5.6 (0e12.8) * Adjusted risk ratio, 1.5 for LR (P ¼ 0.08) Single 4.9 (1.8e10.7; LR group) Estimated 5-yr survival: 87% for LR-free, 58% for LR (P < ) Overall survival at 10 years: 83.6% for LR-free, 43.1% for LR Gragoudas et al 7 Proton beam Single 5.2 (n/a) Relative risk, 4.1 for LR Present study Varied Multicenter 3.7 (0.1e12.6) , 11* Hazard ratio, 6.3 for LR (P < 0.001) COMS ¼ Collaborative Ocular Melanoma Study; LR ¼ local recurrence; n/a ¼ not available. *cumulative estimate. 87

3 Ophthalmology Volume 123, Number 1, January 2016 Results Participating Centers Ten ophthalmic oncology centers from 8 countries (Argentina, Canada, Japan, Russia, Spain, Sweden, The Netherlands, and the United States) in 4 continents (North and South America, Europe, and Asia) participated in this study. Patients Three thousand eight hundred nine patients with uveal melanoma were entered into the online database and staged according to the 7th edition of the AJCC system. Of these, 3377 (89%) records were complete. One hundred eighty-one patient entries were eliminated because of lack of follow-up and 67 were eliminated because of initial presentation with stage 4 disease (metastasis). One hundred eighty-four were removed because of missing or inconsistent key variables. This included 118 with unknown metastasis status, 35 with unknown EXE status, 11 with unknown ciliary body involvement status, and 128 with incomplete or inconsistent data that prevented being assigned a T-size category or prognostic stage. Some patient entries were eliminated for more than 1 of the above reasons. Primary ciliary body and choroidal melanoma was the diagnosis for 3217 patients, and 160 patients had primary iris melanoma. The median follow-up from date of initial diagnosis and staging for the 3217 patients was 3.7 years (95% confidence interval [CI], 3.5e3.8; range, 0.1e12.6 years; Table 1). Ciliary Body and Choroidal Melanoma Recurrence One hundred fifty-two patients (4.7%; n ¼ 152/3217) with ciliary body and choroidal melanoma experienced local recurrence by their last follow-up. Kaplan-Meier point estimates for remaining free of local recurrence were 99% (95% CI, 99%e99%) at 1 year, 93% (95% CI, 92%e94%) at 5 years, and 89% (95% CI, 86%e91%) at 10 years after treatment. Kaplan-Meier estimates of time to local treatment failure are shown graphically in Figure 1A and numerically in Figure 1B. Five years after initial tumor staging, an estimated 7.3% of eyes (95% CI, 6.1%e8.7%) exhibited treatment failure, and an estimated 11% of eyes exhibited treatment failure at 10 years (95% CI, 8.9%e 13.7%). Local recurrence was detected as early as 1 month and as late as 9.8 years after initial tumor staging (Fig 1B). Figure 1. A, The cumulative proportion of patients and (B) a table showing Kaplan-Meier estimates of local recurrence of primary ciliary body and choroidal melanoma after initial tumor staging and treatment. Local Recurrence and Metastasis Kaplan-Meier point estimates at 5 and 10 years after initial tumor staging show that there is a statistically significant difference in the metastasis-free survival for the recurrence and recurrence-free groups (P < 0.001). Forty-three of the 152 patients (28.3%) with local recurrence demonstrated metastasis, compared with 287 (9.4%) of those who were free of recurrence. For the recurrencefree group, the 5- and 10-year metastasis-free estimates were 87% (95% CI, 86%e89%) and 82% (95% CI, 79%e84%), whereas the recurrence group estimates were 71% (95% CI, 62%e78%) and 62% (95% CI, 49%e72%), respectively (Fig 2). In a univariate Cox model, local recurrence increased the risk of metastasis by a hazard ratio (HR) of 6.28 (95% CI, 4.42e8.92). Thus, failure of local control was shown to be associated with a statistically significant (P < 0.001) increase in metastatic disease. Multivariate analysis adjusting for AJCC stage, T-size category, and presence of ciliary body involvement or EXE 88

4 The Ophthalmic Oncology Task Force Uveal Melanoma Recurrence and Metastasis demonstrated that local recurrence was still associated with an increased risk of metastasis (HR, 6.46; 95% CI, 4.52e9.24; P < 0.001). Local Recurrence According to American Joint Committee on Cancer T-Size Category According to T-size category and using the entire 3217-patient cohort, 4.6% of patients in size category T1 (51/1115), 5.7% of patients in size category T2 (64/1128), 4.3% of patients in size category T3 (34/789), and 1.6% of patients in size category T4 (3/185) had local recurrence. The evidence failed to show a trend relationship between T-size category and local recurrence (P ¼ 0.63, log-rank test for trend; Kaplan-Meier estimates did not show a trend). No HRs from a Cox proportional hazards model were statistically significant (all P ¼ 0.12 and higher). Extrascleral Extension and Local Recurrence Of the 152 patients with local recurrence, 7 patients had EXE. Using the entire cohort of 3217, 12.5% (7/56) with EXE demonstrated local recurrence as compared with 4.6% (145/3161) without EXE who demonstrated local recurrence. The HR from a Cox proportional hazards model indicated that the presence of EXE was associated with a higher risk of local recurrence (HR, 3.2; 95% CI, 1.5e6.7; P ¼ 0.003). Time from Local Recurrence to Metastasis Only patients who experienced a local recurrence (n ¼ 152) were included in the analysis of time from local recurrence to metastasis. Of these, 43 patients (28% [43/152]) with local recurrence demonstrated metastasis. Six (3.9%) had already experienced metastasis before local recurrence, 9 (5.9%) had metastasis and local recurrence detected on the same date, 8 (5.3%) had no followup after their local recurrence, and 28 (18.4%) experienced metastasis after local recurrence. One hundred one patients (66.4%) had additional follow-up after their local recurrence date and did not demonstrate metastasis (during that time). After excluding 8 patients because of a lack of follow-up after local recurrence, a cohort of 144 was used to evaluate time to metastasis, with a median follow-up after local recurrence of 2.3 years (95% CI, 1.8e3.0 years). Forty-three of the 144 patients (29.9%) who had a local recurrence also had a metastasis either before, at the same time as, or after local recurrence; the remaining 70.1% of the sample remained free of metastasis by their last follow-up date. The median time to metastasis was 6.8 years; however, in Figure 3, note this estimate was based on a small number remaining at risk for local recurrence with a large 95% CI (95% CI, 6.2eupper limit cannot be calculated). The longest interval from local recurrence to detection of metastasis was 9.8 years. Two (1.4%) patients died without metastasis. Local Recurrence of Iris Melanoma Of the 160 patients with iris melanoma, 5 (3.1%) demonstrated local recurrence by their last follow-up. Of these 5 patients, 2 were in T-size category T1, and 3 were T2. One experienced metastasis 2 years after local recurrence, 3 had follow-up after their local recurrence date (6 months, 6 months, and 3 years) and did not experience metastasis during that time, and 1 had no follow-up after local recurrence (and no metastasis). Kaplan-Meier point estimates (n ¼ 160) for remaining free of local recurrence were 99% (95% CI, 95%e100%) at 1 year, 95% (95% CI, 88%e98%) at 5 years, and 93% (95% CI, 82%e97%) at 10 years. This subset was too small for further statistical analysis. Figure 2. Kaplan-Meier metastasis-free probability for 3217 ciliary body and choroidal melanoma patients with versus without local recurrence (LR) (P < 0.001). Discussion Our study revealed that local tumor recurrence significantly increases the risk of metastatic melanoma (P < 0.001; HR, 6.28). This is the highest HR reported to date. Previous single-center studies evaluating posttreatment local recurrence also have found an increased risk of metastasis (Table 1). For example, Gragoudas et al 7 found a relative risk of 4.1 for those with local recurrence (n ¼ 62) after proton beam irradiation. Vrabec et al 8 reported on cobalt 60 plaque brachytherapy (n ¼ 70) and found a statistically significant decrease in the estimated 5-year survival between their local recurrence-free (87%) and recurrence (58%) groups. In another single-center study, Caujolle et al 6 Figure 3. Kaplan-Meier metastasis-free probability (solid line) and 95% confidence limits (dashed lines) for 144 ciliary body and choroidal melanoma patients with local recurrence. Note the large confidence interval after year 5 resulting from the small number of patients. 89

5 Ophthalmology Volume 123, Number 1, January 2016 (n ¼ 61) noted that survival rates in uveal melanoma patients after proton beam therapy decreased from 83.6% (in those without recurrence) to 55% in those with local recurrence at 10 years. When compared with our relatively large (n ¼ 152) multicenter study, we found that patients with local recurrence fared slightly better, with 71% (5 years) and 62% (10 years) demonstrating metastasis-free survival. Unlike the aforementioned studies, we analyzed local tumor recurrence following the standard of care in multiple international eye cancer centers using their bestrecommended treatment strategies. That is, the study cohort included patients treated with varying types of primary tumor treatment and was not limited to a single treatment method. Thus, local recurrence rates best reflect the standard of care during that decade. This study provides evidence that local recurrence significantly increases the risk of metastasis despite the type of primary tumor treatment. Local radiation failure has been attributed to radiation resistance, misplacement of radioactive plaque, insufficient radiotherapeutic margins, and eye movement (primarily during charged-particle beam therapy). 5,14 Therefore, our findings support the use of methods to improve local control (e.g., intraoperative ultrasound to evaluate plaque placement, slotted plaque radiotherapy, 2e3-mm radiotherapeutic margins, adequate tumor dose and eye fixation during external beam techniques). 15e20 Transpupillary thermotherapy and resection can be augmented by adjuvant radiation treatment. 21e23 Clearly, our findings suggest that all uveal melanoma patients be counseled of greater risks for metastatic disease should their primary tumor treatment fail. This study does not examine the exact mechanism of how local recurrence increased the risk of metastasis. In addition to therapeutic failure, theories include that recurrent tumors may have physiologic, genetic, or anatomic characteristics that made them more malignant or early to metastasize. 11,24e28 It also has been proposed that these biomarkers may contribute both to outcomes of local recurrence and to metastasis. However, this study was not designed to analyze these complex genetic or biological predisposing factors. Rather, it was designed to evaluate the relationship between local recurrence and the incidence of metastatic disease. Certainly, those determining the prognostic efficacy of such tumor-specific biomarkers should consider failure of local control in their calculations. In conclusion, the Ophthalmic Oncology Task Force s uveal melanoma registry clearly demonstrates that multicenter, international data sharing can be used to examine statistically important clinical questions such as the impact of failure of local control on metastatic risk. This study revealed that local recurrence of uveal melanoma is associated with a statistically significant increase in metastasis and that this subgroup of high-risk patients deserves increased surveillance for metastatic disease. Acknowledgment. Princess Margaret Cancer Centre, Toronto, Canada, served as the coordinating center and provided statistical analysis through Christine Massey; Dr. Priya Durairaj provided extensive data collection and oversaw overall data quality; Dr. Yuliya Gavrylyuk and the Health Informatics Research team developed the algorithms and database and managed the Internet website. The Institut Catala Oncologia acknowledges Dr. Juan Pera, Department of Radiotherapy, and Dr. Josep M. Piulats, Department of Medical Oncology, for their participation in uveal melanoma treatment and research. The Leiden University Medical Center acknowledges Professor Stefan de Geus for his contribution to patient care. Writing Committee: Paul T. Finger, MD and Kimberly Chin, OD; The Ophthalmic Oncology Task Force (in order of number of patients contributed): Brenda L. Gallie, MD, E. Rand Simpson, MD, Princess Margaret Cancer Research Centre, University Health Network, Toronto, Canada; Svetlana Saakyan, MD, Anush Amiryan, MD, Vladimir Valskiy, MD, PhD, Moscow Helmholtz Research Institute of Eye Diseases, Moscow, Russia; Paul T. Finger, MD, Kimberly J. Chin, OD, Ekaterina Semenova, MD, The New York Eye Cancer Center, New York, NY, USA; Stefan Seregard, MD, Maria Fili, MD, St. Eriks Eye Hospital, Karolinska Institute, Stockholm, Sweden; Matthew Wilson, MD, Barrett Haik, MD, University of Tennessee Health Science Center Hamilton Eye Institute, Memphis, TN, USA; Jose M. Caminal, MD, Jaume Català, MD, Cristina Gutierrez, MD, Bellvitge University Hospital, Barcelona, Spain; David E. Pelayes, MD, PhD, Anibal Martín Folgar, MD, Carlos G. Durand Hospital, Buenos Aires University, Buenos Aires, Argentina; Martine J. Jager, MD, Mehmet Dogrusöz, MD, Gregorius P.M. Luyten, MD, Leiden University Medical Center, Leiden, The Netherlands; Arun Singh, MD, Andrew P. Schachat, MD, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA; Shigenobu Suzuki, MD, Yukiko Aihara, MD; National Cancer Center, Tokyo, Japan. References 1. DeVita Jr VT, DeVita J, Theodore S, et al., eds. Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia: Wolters Kluwer; Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 2002;109: Chang MY, McCannel TA. Local treatment failure after globeconserving therapy for choroidal melanoma. Br J Ophthalmol 2013;97: Moshfeghi DM, Moshfeghi AA, Finger PT. Enucleation. Surv Ophthalmol 2000;44: Finger PT. Intraocular melanoma. In: Vincent Jr VT, DeVita J, Theodore S, et al., eds. Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia: Wolters Kluwer; 2015: Caujolle JP, Paoli V, Chamorey E, et al. Local recurrence after uveal melanoma proton beam therapy: recurrence types and prognostic consequences. Int J Radiat Oncol Biol Phys 2013;85: Gragoudas ES, Lane AM, Munzenrider J, et al. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc 2002;100:43 8. discussion 48e Vrabec TR, Augsburger JJ, Gamel JW, et al. Impact of local tumor relapse on patient survival after cobalt 60 plaque radiotherapy. Ophthalmology 1991;98: Finger PT; 7th Edition AJCC-UICC Ophthalmic Oncology Task Force. The 7th edition AJCC staging system for eye cancer: an international language for ophthalmic oncology. Arch Pathol Lab Med 2009;133: The Ophthalmic Oncology Task Force. Ophthalmic sites. In: Edge SB, Byrd DR, Compton CC, et al., eds. AJCC Cancer 90

6 The Ophthalmic Oncology Task Force Uveal Melanoma Recurrence and Metastasis Staging Manual. 7th ed. New York: Springer-Verlag; 2009: The Ophthalmic Oncology Task Force. International validation of the American Joint Committee on Cancer s 7th Edition classification of uveal melanoma. JAMA Ophthalmol 2015;133: The Ophthalmic Oncology Task Force. Malignant melanoma of the uvea. In: Edge SB, Byrd DR, Compton CC, et al., eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer- Verlag; 2009: Greenwood M. The natural duration of cancer. Reports on Public Health and Medical Subjects. London: Her Majesty s Stationery Office. 1926;33:1e Char DH, Kroll S, Phillips TL, Quivey JM. Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. Ophthalmology 2002;109: Finger PT, Chin KJ, Tena LB. A five-year study of slotted eye plaque radiation therapy for choroidal melanoma: near, touching, or surrounding the optic nerve. Ophthalmology 2012;119: Chiu-Tsao ST, Astrahan MA, Finger PT, et al. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS. Med Phys 2012;39: The Ophthalmic Oncology Task Force. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 2014;13: Harbour JW, Murray TG, Byrne SF, et al. Intraoperative echographic localization of iodine 125 episcleral radioactive plaques for posterior uveal melanoma. Retina 1996;16: Barker CA, Francis JH, Cohen GN, et al. (106)Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence. Brachytherapy 2014;13: Rivard MJ, Chiu-Tsao ST, Finger PT, et al. Comparison of dose calculation methods for brachytherapy of intraocular tumors. Med Phys 2011;38: Damato B. Adjunctive plaque radiotherapy after local resection of uveal melanoma. Front Radiat Ther Oncol 1997;30: Damato BE, Paul J, Foulds WS. Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br J Ophthalmol 1996;80: Sagoo MS, Shields CL, Mashayekhi A, et al. Plaque radiotherapy for juxtapapillary choroidal melanoma: tumor control in 650 consecutive cases. Ophthalmology 2011;118: Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012;119: Finger PT, Chin K, Iacob CE. 18-Fluorine-labelled 2-deoxy-2- fluoro-d-glucose positron emission tomography/computed tomography standardised uptake values: a non-invasive biomarker for the risk of metastasis from choroidal melanoma. Br J Ophthalmol 2006;90: Kujala E, Damato B, Coupland SE, et al. Staging of ciliary body and choroidal melanomas based on anatomic extent. J Clin Oncol 2013;31: Kivela T, Kujala E. Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond. Eye (Lond) 2013;27: Finger PT. Eye: choroidal melanoma, retinoblastoma, ocular adnexal lymphoma and eyelid cancers. In: O Sullivan B, Brierly J, D Cruz A, et al., eds. UICC Manual of Clinical Oncology. 9th ed. Chichester: John Wiley & Sons, Ltd; 2015: Footnotes and Financial Disclosures Originally received: July 27, Final revision: September 11, Accepted: September 11, Available online: October 21, Manuscript no The New York Eye Cancer Center, New York, New York. Presented at: American Academy of Ophthalmology Annual Meeting, November 2015, Las Vegas, Nevada, Paul T. Finger, MD, on behalf of the Ophthalmic Oncology Task Force. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Supported by The Eye Cancer Foundation; the Paul T. Finger, MD, Fund at Princess Margaret Cancer Centre, Toronto, Canada; and John and Myrna Daniels (Toronto, Ontario, Canada, and New York, NY). The sponsors had no role in the design or conduct of this research. Author Contributions: Conception and design: Finger, Simpson, Ophthalmic Oncology Task Force Analysis and interpretation: Finger, Chin, Ophthalmic Oncology Task Force Data collection: Ophthalmic Oncology Task Force Obtained funding: Finger Overall responsibility: Finger, Ophthalmic Oncology Task Force Abbreviations and Acronyms: AJCC ¼ American Joint Committee on Cancer; CBC ¼ ciliary body and choroidal; CI ¼ confidence interval; EXE ¼ extrascleral extension; HR ¼ hazard ratio; T size ¼ tumor size (T-size refers to AJCC ct stage). Correspondence: Paul T. Finger, MD, New York Eye Cancer Center, 115 East 61st Street, Suite 5A/B, New York, NY pfinger@eyecancer.com. 91

Gene Expression Profiling has been proposed as a method of risk stratification for uveal melanoma.

Gene Expression Profiling has been proposed as a method of risk stratification for uveal melanoma. Last Review Status/Date: September 2014 Description Page: 1 of 5 Gene Expression Profiling has been proposed as a method of risk stratification for uveal melanoma. Background Uveal melanoma Uveal melanoma,

More information

Transvitreal Fine Needle Aspiration Biopsy of Choroidal Melanoma via Pars Plana Vitrectomy

Transvitreal Fine Needle Aspiration Biopsy of Choroidal Melanoma via Pars Plana Vitrectomy Surgical Technique Is pars plana vitrectomy a safe method for performing fine needle aspiration biopsy of choroidal melanoma? What are the rates of complications? Clinical Characteristics Do tumor thickness

More information

Gender Differences in Clinical Presentation and Prognosis of Uveal Melanoma METHODS. Patients

Gender Differences in Clinical Presentation and Prognosis of Uveal Melanoma METHODS. Patients Anatomy and Pathology Gender Differences in Clinical Presentation and Prognosis of Uveal Melanoma Ofira Zloto, Jacob Pe er, and Shahar Frenkel PURPOSE. We examined the clinical differences in manifestation

More information

UCSF Uveal Melanoma Program: Outcomes with Proton Beam Radiation Therapy Kavita K. Mishra, M.D., M.P.H. UCSF Comprehensive Cancer Center

UCSF Uveal Melanoma Program: Outcomes with Proton Beam Radiation Therapy Kavita K. Mishra, M.D., M.P.H. UCSF Comprehensive Cancer Center Disclosures UCSF Uveal Melanoma Program: Outcomes with Proton Beam Radiation Therapy No disclosures Kavita K. Mishra, M.D., M.P.H. UCSF Comprehensive Cancer Center UCSF Uveal Melanoma Program: Ocular Melanoma

More information

FEP Medical Policy Manual

FEP Medical Policy Manual FEP Medical Policy Manual Last Review: December 2016 Effective Date: January 15, 2017 Related Policies None Gene Expression Profiling for Uveal Melanoma Summary Uveal melanoma is associated with a high

More information

Can Protons replace Eye Brachytherapy? 1 Department of Radiation Oncology

Can Protons replace Eye Brachytherapy? 1 Department of Radiation Oncology Can Protons replace Eye Brachytherapy? Richard Pötter 1,2, Roman Dunavölgyi 3, Karin Dieckmann 1, Dietmar Georg 1,2 1 Department of Radiation Oncology 2 Christian Doppler Laboratory for Medical Radiation

More information

Gene Expression Profiling for Melanoma

Gene Expression Profiling for Melanoma Medical Policy Manual Genetic Testing, Policy No. 29 Gene Expression Profiling for Melanoma Next Review: April 2019 Last Review: April 2018 Effective: June 1, 2018 IMPORTANT REMINDER Medical Policies are

More information

Research Article Outcomes and Control Rates for I-125 Plaque Brachytherapy for Uveal Melanoma: A Community-Based Institutional Experience

Research Article Outcomes and Control Rates for I-125 Plaque Brachytherapy for Uveal Melanoma: A Community-Based Institutional Experience ISRN Ophthalmology, Article ID 95975, 7 pages http://dx.doi.org/1.1155/214/95975 Research Article Outcomes and Control Rates for I-125 Plaque Brachytherapy for Uveal Melanoma: A Community-Based Institutional

More information

Case Rep Oncol 2012;5: DOI: /

Case Rep Oncol 2012;5: DOI: / This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the article

More information

Vitreoretinal surgical management In ocular oncology

Vitreoretinal surgical management In ocular oncology www.ophtalmique.ch Vitreoretinal surgical management In ocular oncology Pournaras Jean-Antoine C Vitreoretinal Surgery Unit 1. Surgical resection after proton beam therapy 2. Ocular Biopsy 3. RD in advanced

More information

Long-Term Survivors with Metastatic Uveal Melanoma

Long-Term Survivors with Metastatic Uveal Melanoma The Open Ophthalmology Journal, 2012, 6, 49-53 49 Long-Term Survivors with Metastatic Uveal Melanoma Open Access Dominic M. Buzzacco,1, Mohamed H. Abdel-Rahman,1,2, Stanley Park 1, Frederick Davidorf 1,

More information

Management and Outcome of Uveal Melanoma in a Single Tertiary Cancer Center in Jordan

Management and Outcome of Uveal Melanoma in a Single Tertiary Cancer Center in Jordan Original Article doi:./tjpath.. Management and Outcome of Uveal Melanoma in a Single Tertiary Cancer Center in Jordan Ahmed Zewar, Ibrahim Nawaiseh, Imad Jaradat, Jakub Khzouz, Khaleel AlRawashdeh, Ghadeer

More information

National Guidelines for the management of uveal melanoma. Sponsored by Melanoma Focus

National Guidelines for the management of uveal melanoma. Sponsored by Melanoma Focus National Guidelines for the management of uveal melanoma Sponsored by Melanoma Focus GDG Members Paul Nathan (Chair Oncologist Mt Vernon) Kieran McGuirk (Ocumel) Lesley Kirkpatrick (Ocumel) Kathryn Curtis

More information

Surveillance following treatment of primary ocular melanoma

Surveillance following treatment of primary ocular melanoma Surveillance following treatment of primary ocular melanoma Introduction 50% of UM patients relapse with predominantly liver metastases Risk of metastatic disease can be predicted relatively accurately

More information

Tall, dark and.. Uh oh

Tall, dark and.. Uh oh Tall, dark and.. Uh oh Jesse L. Berry, MD Arizona Ophthalmology Society 2017 Ocular Oncology Service USC Eye Institute Financial Disclosures Research Support: Bright Eyes Nautica Foundation Knights Templar

More information

Introduction ORIGINAL RESEARCH

Introduction ORIGINAL RESEARCH Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey

More information

FEP Medical Policy Manual

FEP Medical Policy Manual FEP Medical Policy Manual Effective Date: July 15, 2018 Related Policies: 8.01.10 Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions Gene Expression Profiling for Uveal Melanoma

More information

Retina Center of Oklahoma Sam S. Dahr, M.D. Adult Intraocular Tumors

Retina Center of Oklahoma   Sam S. Dahr, M.D. Adult Intraocular Tumors Adult Intraocular Tumors Sam S. Dahr, M.D. Retina Center of Oklahoma www.retinacenteroklahoma.com www.rcoklahoma.com Table of Contents Posterior uveal malignant melanoma Uveal metastasis Uveal melanoma

More information

Dosimetric Benefit of a New Ophthalmic Radiation Plaque

Dosimetric Benefit of a New Ophthalmic Radiation Plaque International Journal of Radiation Oncology biology physics www.redjournal.org Physics Contribution Dosimetric Benefit of a New Ophthalmic Radiation Plaque Gaurav Marwaha, MD,*,x Allan Wilkinson, PhD,*,x

More information

Factory loaded, sterilized, ready to implant plaques:!

Factory loaded, sterilized, ready to implant plaques:! in partnership with Factory loaded, sterilized, ready to implant plaques: Eye Physics plaques. 2 nd generation plaques (cast in 18K gold from hand carved wax prototypes). 3 rd generation plaques (cast

More information

Published Evidence. Hicks C, Foss AJE, Hungerford JL: Predictive power of screening tests for metastasis in uveal melanoma. Eye 12: , 1998

Published Evidence. Hicks C, Foss AJE, Hungerford JL: Predictive power of screening tests for metastasis in uveal melanoma. Eye 12: , 1998 Published Evidence Hicks C, Foss AJE, Hungerford JL: Predictive power of screening tests for metastasis in uveal melanoma. Eye 12:945-948, 1998 245 patients UM screened at diagnosis with FBC, LFT, CXR,

More information

Evaluation of AJCC, UICC, and Brigham and Women's Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma

Evaluation of AJCC, UICC, and Brigham and Women's Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma Evaluation of AJCC, UICC, and Brigham and Women's Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma Karia, et al Methods Details of data collectionfeatures of primary tumors including anatomic

More information

C ancer cells require a great deal of sugar (glucose) for. PET/CT imaging: detection of choroidal melanoma SCIENTIFIC REPORT

C ancer cells require a great deal of sugar (glucose) for. PET/CT imaging: detection of choroidal melanoma SCIENTIFIC REPORT 265 SCIENTIFIC REPORT PET/CT imaging: detection of choroidal melanoma S Reddy, M Kurli, L B Tena, P T Finger... Aim: To determine the size of untreated choroidal melanomas resolved by whole body positron

More information

ROPES eye plaque dosimetry: commissioning and verification of an ophthalmic brachytherapy treatment planning system

ROPES eye plaque dosimetry: commissioning and verification of an ophthalmic brachytherapy treatment planning system University of Wollongong Research Online Faculty of Engineering and Information Sciences - Papers: Part A Faculty of Engineering and Information Sciences 2013 ROPES eye plaque dosimetry: commissioning

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our

More information

Peritoneal Involvement in Stage II Colon Cancer

Peritoneal Involvement in Stage II Colon Cancer Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.

More information

Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases

Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation

More information

M ALIGNANT MELANOMA OF THE UVEA STAGING FORM

M ALIGNANT MELANOMA OF THE UVEA STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX T0 a a a d b c d a TUMOR SIZE: S TAGE C ATEGORY D EFINITIONS LATERALITY:

More information

Continuing Medical Education

Continuing Medical Education Continuing Medical Education The Department of Radiation Oncology offers free Continuing Medical Education credit to readers who read the designated CME article and successfully complete a follow-up test

More information

We have previously reported good clinical results

We have previously reported good clinical results J Neurosurg 113:48 52, 2010 Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional

More information

Systemic and ocular follow-up after conservative management of an intraocular tumor

Systemic and ocular follow-up after conservative management of an intraocular tumor Systemic and ocular follow-up after conservative management of an intraocular tumor 7 th Thessaloniki international Vitreo Retinal Summer School,26.6-1.7.2017 L. Zografos MD Jules Gonin Eye Hospital Periodic

More information

Method for verifying the air kerma strength of I-125 plaques for the treatment of ocular melanoma

Method for verifying the air kerma strength of I-125 plaques for the treatment of ocular melanoma JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 15, NUMBER 4, 2014 Method for verifying the air kerma strength of I-125 plaques for the treatment of ocular melanoma L. W. Zimmermann, 1a D. Allan Wilkinson

More information

METHODS FOR coding the

METHODS FOR coding the Assessment of Metastatic Disease Status at Death in 435 Patients With Large Choroidal Melanoma in the Collaborative Ocular Melanoma Study (COMS) COMS Report No. 15 The Collaborative Ocular Melanoma Study

More information

After primary tumor treatment, 30% of patients with malignant

After primary tumor treatment, 30% of patients with malignant ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant

More information

Visionary News. Happiness can be found in giving to others. ECF Lunch - NYC

Visionary News. Happiness can be found in giving to others. ECF Lunch - NYC S P R I N G 2 0 1 0 the Visionary News Happiness can be found in giving to others Do You Speak The EyeCare Foundation is now The Eye Cancer Foundation Starting January 1 st, 2010, ECF will stand for The

More information

Ruthenium-106 plaque brachytherapy in the primary management of ocular medulloepithelioma

Ruthenium-106 plaque brachytherapy in the primary management of ocular medulloepithelioma Poon, DS; Reich, E; Smith, VM; Kingston, J; Reddy, MA; Hungerford, JL; Sagoo, MS; (2015) Ruthenium-106 Plaque Brachytherapy in the Primary Management of Ocular Medulloepithelioma. Ophthalmology, 122 (9)

More information

MEDICAL POLICY SUBJECT: TRANSPUPILLARY THERMOTHERAPY. POLICY NUMBER: CATEGORY: Technology Assessment

MEDICAL POLICY SUBJECT: TRANSPUPILLARY THERMOTHERAPY. POLICY NUMBER: CATEGORY: Technology Assessment MEDICAL POLICY SUBJECT: TRANSPUPILLARY EDITED DATE: 08/20/15, 08/18/16, 08/17/17 PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.

More information

Mesectodermal suprauveal iridociliary leiomyoma: Transscleral excision without postoperative iris defect

Mesectodermal suprauveal iridociliary leiomyoma: Transscleral excision without postoperative iris defect 4 Chapter Mesectodermal suprauveal iridociliary leiomyoma: Transscleral excision without postoperative iris defect Lubna Razzaq 1, Ekaterina A Semenova 2, Marina Marinkovic 1, Rob JW de Keizer 1, Sjoerd

More information

Best Papers. F. Fusco

Best Papers. F. Fusco Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical

More information

Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience

Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Poster No.: RO-0003 Congress: RANZCR FRO 2012 Type: Scientific Exhibit Authors: C. Harrington,

More information

Plaque Radiotherapy in Recurrent or Incomplete- Excised Conjunctival Squamous Cell Carcinoma and Melanoma

Plaque Radiotherapy in Recurrent or Incomplete- Excised Conjunctival Squamous Cell Carcinoma and Melanoma Plaque Radiotherapy in Recurrent or Incomplete- Excised Conjunctival Squamous Cell Carcinoma and Melanoma Masood Naseripour, MD 1 Mohsen Bahmani-Kashkouli, MD 1 Ramin Jaberi, MS 2 Gholam-Hossein Aghaee,

More information

The right middle lobe is the smallest lobe in the lung, and

The right middle lobe is the smallest lobe in the lung, and ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,

More information

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,

More information

A REANALYSIS OF THE COLLABORATIVE OCULAR MELANOMA STUDY MEDIUM TUMOR TRIAL EYE PLAQUE DOSIMETRY

A REANALYSIS OF THE COLLABORATIVE OCULAR MELANOMA STUDY MEDIUM TUMOR TRIAL EYE PLAQUE DOSIMETRY doi:10.1016/s0360-3016(03)00211-6 Int. J. Radiation Oncology Biol. Phys., Vol. 56, No. 3, pp. 889 898, 2003 Copyright 2003 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/03/$ see front

More information

CLINICAL SCIENCES. Pretreatment Characteristics and Response to Plaque Radiation Therapy

CLINICAL SCIENCES. Pretreatment Characteristics and Response to Plaque Radiation Therapy CLINICAL SCIENCES Subfoveal Choroidal Melanoma Pretreatment Characteristics and Response to Plaque Radiation Therapy Hadas Newman, MD; Kimberly J. Chin, OD; Paul T. Finger, MD Objective: To evaluate the

More information

A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using 125 I COMS plaques

A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using 125 I COMS plaques Lee et al. Radiation Oncology (2018) 13:221 https://doi.org/10.1186/s13014-018-1166-z RESEARCH Open Access A practical approach to estimating optic disc dose and macula dose without treatment planning

More information

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert

More information

Enhancing survival prognostication in. integrating pathologic, clinical and genetic predictors of metastasis

Enhancing survival prognostication in. integrating pathologic, clinical and genetic predictors of metastasis The Royal Liverpool and Broadgreen University Hospitals NHS Trust NHS Enhancing survival prognostication in patients with choroidal melanoma by integrating pathologic, clinical and genetic predictors of

More information

M etastatic disease influences patient management; Whole body PET/CT for initial staging of choroidal melanoma SCIENTIFIC REPORT

M etastatic disease influences patient management; Whole body PET/CT for initial staging of choroidal melanoma SCIENTIFIC REPORT 1270 SCIENTIFIC REPORT Whole body PET/CT for initial staging of choroidal P T Finger, M Kurli, S Reddy, L B Tena, A C Pavlick... Aim: To investigate the value of whole body positron emission tomography/computed

More information

Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery

Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery ORIGINAL ARTICLE Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery Ann C. Raldow, BS,* Veronica L. Chiang, MD,w Jonathan P.

More information

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic

More information

Proton Radiation Therapy of Ocular Melanoma at PSI

Proton Radiation Therapy of Ocular Melanoma at PSI Proton Radiation Therapy of Ocular Melanoma at PSI G. Goitein*, A. Schalenbourg, J. Verwey*, A. Bolsi*, C. Ares*, L. Chamot, E. Hug*, L. Zografos *Paul Scherrer Institut, 5232 Villigen PSI; Hôpital Ophtalmique,

More information

Protocol for the Examination of Specimens From Patients With Uveal Melanoma

Protocol for the Examination of Specimens From Patients With Uveal Melanoma Protocol for the Examination of Specimens From Patients With Uveal Melanoma Version: Protocol Posting Date: June 2017 Includes ptnm requirements from the 8 th Edition, AJCC Staging Manual For accreditation

More information

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,

More information

Relationship of regression pattern to recurrence in retinoblastoma

Relationship of regression pattern to recurrence in retinoblastoma 12 BritishJournal ofophthalmology 1993; 77: 12-16 Relationship of regression pattern to recurrence in retinoblastoma A D Singh, D Garway-Heath, S Love, P N Plowman, J Kingston, J L Hungerford Ophthalmology

More information

Seed coordinates of a new COMS-like 24 mm plaque verified using the FARO Edge

Seed coordinates of a new COMS-like 24 mm plaque verified using the FARO Edge JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 16, NUMBER 6, 2015 Seed coordinates of a new COMS-like 24 mm plaque verified using the FARO Edge Sarah E. McCauley Cutsinger, 1a Keith M. Furutani, 1

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Gene Expression Profiling for Uveal Melanoma Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Gene Expression Profiling for Uveal Melanoma Professional

More information

Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma

Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma ISRN Dermatology Volume 2013, Article ID 586915, 5 pages http://dx.doi.org/10.1155/2013/586915 Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome

More information

Prognostic value of the 8 th tumor-node-metastasis classification for follicular carcinoma and poorly differentiated carcinoma of the thyroid in Japan

Prognostic value of the 8 th tumor-node-metastasis classification for follicular carcinoma and poorly differentiated carcinoma of the thyroid in Japan 2018, 65 (6), 621-627 ORIGINAL Prognostic value of the 8 th tumor-node-metastasis classification for follicular carcinoma and poorly differentiated carcinoma of the thyroid in Japan Yasuhiro Ito 1), Akira

More information

points causes features therapy collaborative ocular melanoma study prognosis Choroid Nevus

points causes features therapy collaborative ocular melanoma study prognosis Choroid Nevus The Game of Uveal Melanoma Carol Shields MD Oncology Service Wills Eye Hospital Philadelphia PA USA www.fighteyecancer.com Oncology Service Wills Eye Institute points causes features therapy collaborative

More information

Malignant melanoma of the uvea disseminates purely hematogenously, Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma

Malignant melanoma of the uvea disseminates purely hematogenously, Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma Emma Kujala, 1 Teemu Mäkitie, 2 and Tero Kivelä 1,2 From the 1 Ocular Oncology Service and 2 Ophthalmic Pathology Laboratory, Department

More information

Carlo Mosci. Ocular Oncology Service Galliera Hospital Genova Italy (www.galliera.it)

Carlo Mosci. Ocular Oncology Service Galliera Hospital Genova Italy (www.galliera.it) RADIATION INDUCED Carlo Mosci Ocular Oncology Service Galliera Hospital Genova Italy (www.galliera.it) "Working Day - Radiation Side Effects" carlo.mosci@galliera.it RADIATION INDUCED Different treatment

More information

Principal Investigator. General Information. Conflict of Interest Published on The YODA Project (http://yoda.yale.edu)

Principal Investigator. General Information. Conflict of Interest Published on The YODA Project (http://yoda.yale.edu) Principal Investigator First Name: Antonio Last Name: Finelli Degree: MD, MSc, FRCSC Primary Affiliation: Princess Margaret Cancer Centre E-mail: antonio.finelli@uhn.ca Phone number: 416-946-4501 x2851

More information

CLINICAL SCIENCES. Metastatic Melanoma Death Rates by Anatomic Site After Proton Beam Irradiation for Uveal Melanoma

CLINICAL SCIENCES. Metastatic Melanoma Death Rates by Anatomic Site After Proton Beam Irradiation for Uveal Melanoma CLINICAL SCIENCES Metastatic Melanoma Death Rates by Anatomic Site After Proton Beam Irradiation for Uveal Melanoma Wenjun Li, MS; Evangelos S. Gragoudas, MD; Kathleen M. Egan, ScD Background: Ciliary

More information

An Interactive TreatmentPlanning System For Ophthalmic Plaque Radiotherapy

An Interactive TreatmentPlanning System For Ophthalmic Plaque Radiotherapy An Interactive TreatmentPlanning System For Ophthalmic Plaque Radiotherapy Melvin A. Astrahan, PH.D.,¹ Gary Luxton, PH.D.,¹ Gabor Jozsef, PH.D.,¹ Thomas D. Kampp, PH.D.,¹ Peter E. Liggett, M.D.,² Michael

More information

Survival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer

Survival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer Survival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer Jayashree Kalpathy-Cramer PhD 1, William Hersh, MD 1, Jong Song Kim, PhD

More information

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon

More information

Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer

Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department

More information

Gene Expression Profiling for Uveal Melanoma

Gene Expression Profiling for Uveal Melanoma Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Visual Acuity, Contrast Sensitivity and Color Vision Three Years After Iodine-125 Brachytherapy for Choroidal and Ciliary Body Melanoma

Visual Acuity, Contrast Sensitivity and Color Vision Three Years After Iodine-125 Brachytherapy for Choroidal and Ciliary Body Melanoma Send Orders for Reprints to reprints@benthamscience.ae The Open Ophthalmology Journal, 2015, 9, 131-135 131 Open Access Visual Acuity, Contrast Sensitivity and Color Vision Three Years After Iodine-125

More information

CLINICAL SCIENCES. Conclusions: A distinctive postbrachytherapy regression

CLINICAL SCIENCES. Conclusions: A distinctive postbrachytherapy regression horoidal Melanomas With a ollar-utton onfiguration Response Pattern fter Iodine 125 rachytherapy Dennis M. Robertson, MD LINIL SIENES Objective: To describe a distinctive type of postbrachytherapy response

More information

Utility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer

Utility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Utility of F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Ngoc Ha Le 1*, Hong Son Mai 1, Van Nguyen Le 2, Quang Bieu Bui 2 1 Department

More information

Advances in gastric cancer: How to approach localised disease?

Advances in gastric cancer: How to approach localised disease? Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation

More information

A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia

A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,

More information

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,

More information

Lymphadenectomy in RCC: Yes, No, Clinical Trial?

Lymphadenectomy in RCC: Yes, No, Clinical Trial? Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University

More information

Outcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer

Outcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative

More information

PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING

PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING ANATOMY ANATOMY CONT ANATOMY CONT. ANATOMY CONT. EYE OF A CHILD Normal tissue tolerance doses (in conventional #) TD 5/5 TD 50/5 Endpoint Gy Gy Optic nerve

More information

Uveal Melanoma. Protocol applies to malignant melanoma of the uvea.

Uveal Melanoma. Protocol applies to malignant melanoma of the uvea. Uveal Melanoma Protocol applies to malignant melanoma of the uvea. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition Procedures Cytology (No Accompanying Checklist) Biopsy (No Accompanying

More information

Routes of Extraocular Extension of Uveal Melanoma

Routes of Extraocular Extension of Uveal Melanoma Routes of Extraocular Extension of Uveal Melanoma Risk Factors and Influence on Survival Probability Sarah E. Coupland, MBBS, PhD, 1 Ian Campbell, MD, FRCS, 2 Bertil Damato, MD, PhD 3 Purpose: To correlate

More information

Clinical analysis of 29 cases of nasal mucosal malignant melanoma

Clinical analysis of 29 cases of nasal mucosal malignant melanoma 1166 Clinical analysis of 29 cases of nasal mucosal malignant melanoma HUANXIN YU and GANG LIU Department of Otorhinolaryngology Head and Neck Surgery, Tianjin Huanhu Hospital, Tianjin 300060, P.R. China

More information

Xiang Hu*, Liang Cao*, Yi Yu. Introduction

Xiang Hu*, Liang Cao*, Yi Yu. Introduction Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang

More information

Case Study. Monocular Malignant Melanoma

Case Study. Monocular Malignant Melanoma Case Study Monocular Malignant Melanoma Case History A 52 year old Caucasian female presented with a number of naevi on the skin and a right ciliary body malignant melanoma twelve years ago and had an

More information

age or poor performance status

age or poor performance status Journal of Radiation Research Advance Access published May 17, 2013 Journal of Radiation Research, 2013, pp 1 6 doi: 10.1093/jrr/rrt060 198 Au grain implantation for early tongue cancer in patients of

More information

Title: What is the role of pre-operative PET/PET-CT in the management of patients with

Title: What is the role of pre-operative PET/PET-CT in the management of patients with Title: What is the role of pre-operative PET/PET-CT in the management of patients with potentially resectable colorectal cancer liver metastasis? Pablo E. Serrano, Julian F. Daza, Natalie M. Solis June

More information

Lymph node ratio as a prognostic factor in stage III colon cancer

Lymph node ratio as a prognostic factor in stage III colon cancer Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com

More information

POSITRON EMISSION TOMOGRAPHY (PET)

POSITRON EMISSION TOMOGRAPHY (PET) Status Active Medical and Behavioral Health Policy Section: Radiology Policy Number: V-27 Effective Date: 08/27/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should

More information

Analysis of the outcome of young age tongue squamous cell carcinoma

Analysis of the outcome of young age tongue squamous cell carcinoma Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of

More information

M alignant melanoma of the uvea causes clinical metastases

M alignant melanoma of the uvea causes clinical metastases 333 CLINICAL SCIENCE Mode of presentation and time to treatment of uveal melanoma in Finland S Eskelin, T Kivelä... See end of article for authors affiliations... Correspondence to: Sebastian Eskelin,

More information

The 7th Edition of TNM in Lung Cancer.

The 7th Edition of TNM in Lung Cancer. 10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic

More information

Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy

Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy SAGE-Hindawi Access to Research Lung Cancer International Volume 2011, Article ID 152125, 4 pages doi:10.4061/2011/152125 Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients:

More information

Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma

Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma pissn 1598-2998, eissn 25-9256 Cancer Res Treat. 218;5(4):1238-1251 Original Article https://doi.org/1.4143/crt.217.534 Open Access Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma

More information

Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy

Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy Respiratory Medicine Volume 2015, Article ID 570314, 5 pages http://dx.doi.org/10.1155/2015/570314 Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication

More information

Uveal melanoma is the most common primary intraocular

Uveal melanoma is the most common primary intraocular Genetics Higher Percentage of FISH-Determined Monosomy 3 and 8q Amplification in Uveal Melanoma Cells relate to Poor Patient Prognosis Thomas van den Bosch, 1,2 Jackelien G. M. van Beek, 2,3 Jolanda Vaarwater,

More information

Cyberknife Radiosurgery for Uveal Melanoma

Cyberknife Radiosurgery for Uveal Melanoma Cyberknife Radiosurgery for Uveal Melanoma Kirsten Eibl, Alexander Muacevic, Anselm Kampik Cyberknife Center Munich-Großhadern in cooperation with the University Hospital of the University Munich Uveal

More information

A new score predicting the survival of patients with spinal cord compression from myeloma

A new score predicting the survival of patients with spinal cord compression from myeloma Douglas et al. BMC Cancer 2012, 12:425 RESEARCH ARTICLE Open Access A new score predicting the survival of patients with spinal cord compression from myeloma Sarah Douglas 1, Steven E Schild 2 and Dirk

More information

J Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer

More information

Research Article Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy and Extended Lymphadenectomy

Research Article Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy and Extended Lymphadenectomy International Surgical Oncology Volume 2012, Article ID 307670, 7 pages doi:10.1155/2012/307670 Research Article Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: charged_particle_radiotherapy 3/12/96 5/2017 5/2018 5/2017 Description of Procedure or Service Charged-particle

More information

DECISIONDx BIOMARKER TESTS

DECISIONDx BIOMARKER TESTS DECISIONDx BIOMARKER TESTS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and

More information